Efipladib |CAS#381683-94-9 | phospholipase inhibitor

MedKoo Cat#: 530102 | Name: Efipladib

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Efipladib, also known as PLA902, is a phospholipase inhibitor potentially for the treatment of osteoarthritis and rheumatoid arthritis. In studies, Efipladib was shown to decrease nociceptive responses without affecting PGE2 levels in the cerebral spinal fluid.

Chemical Structure

Efipladib

CAS#381683-94-9

Theoretical Analysis

MedKoo Cat#: 530102

Name: Efipladib

CAS#: 381683-94-9

Chemical Formula: C40H35Cl3N2O4S

Exact Mass: 744.1383

Molecular Weight: 746.14

Elemental Analysis: C, 64.39; H, 4.73; Cl, 14.25; N, 3.75; O, 8.58; S, 4.30

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Efipladib; PLA-902; PLA 902; PLA902;

IUPAC/Chemical Name

4-(3-(1-benzhydryl-5-chloro-2-(2-(((3,4-dichlorophenyl)methyl)sulfonamido)ethyl)-1H-indol-3-yl)propyl)benzoic

InChi Key

HIZOPJQOPKRKFM-UHFFFAOYSA-N

InChi Code

InChI=1S/C40H35Cl3N2O4S/c41-32-19-21-37-34(25-32)33(13-7-8-27-14-17-31(18-15-27)40(46)47)38(22-23-44-50(48,49)26-28-16-20-35(42)36(43)24-28)45(37)39(29-9-3-1-4-10-29)30-11-5-2-6-12-30/h1-6,9-12,14-21,24-25,39,44H,7-8,13,22-23,26H2,(H,46,47)

SMILES Code

O=C(O)C1=CC=C(CCCC2=C(CCNS(=O)(CC3=CC=C(Cl)C(Cl)=C3)=O)N(C(C4=CC=CC=C4)C5=CC=CC=C5)C6=C2C=C(Cl)C=C6)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 746.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Nickerson-Nutter CL, Goodwin D, Shen MW, Damphousse C, Duan W, Samad TA, McKew JC, Lee KL, Zaleska MM, Mollova N, Clark JD. The cPLA2α inhibitor efipladib decreases nociceptive responses without affecting PGE2 levels in the cerebral spinal fluid. Neuropharmacology. 2011 Mar;60(4):633-41. doi: 10.1016/j.neuropharm.2010.11.025. PubMed PMID: 21146550. 2: McKew JC, Lee KL, Shen MW, Thakker P, Foley MA, Behnke ML, Hu B, Sum FW, Tam S, Hu Y, Chen L, Kirincich SJ, Michalak R, Thomason J, Ipek M, Wu K, Wooder L, Ramarao MK, Murphy EA, Goodwin DG, Albert L, Xu X, Donahue F, Ku MS, Keith J, Nickerson-Nutter CL, Abraham WM, Williams C, Hegen M, Clark JD. Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl )-1H-indol-3-yl]propyl}benzoic acid, efipladib. J Med Chem. 2008 Jun 26;51(12):3388-413. doi: 10.1021/jm701467e. PubMed PMID: 18498150. 3: Yao M, Xie C, Kiang MY, Teng Y, Harman D, Tiffen J, Wang Q, Sved P, Bao S, Witting P, Holst J, Dong Q. Targeting of cytosolic phospholipase A2α impedes cell cycle re-entry of quiescent prostate cancer cells. Oncotarget. 2015 Oct 27;6(33):34458-74. doi: 10.18632/oncotarget.5277. PubMed PMID: 26416244; PubMed Central PMCID: PMC4741466. 4: Niknami M, Vignarajan S, Yao M, Hua S, Witting PK, Kita Y, Shimizu T, Sved P, Patel MI, Dong Q. Decrease in expression or activity of cytosolic phospholipase A2alpha increases cyclooxygenase-1 action: A cross-talk between key enzymes in arachidonic acid pathway in prostate cancer cells. Biochim Biophys Acta. 2010 Jul;1801(7):731-7. doi: 10.1016/j.bbalip.2010.03.003. PubMed PMID: 20227521. 5: Zheng Z, He X, Xie C, Hua S, Li J, Wang T, Yao M, Vignarajan S, Teng Y, Hejazi L, Liu B, Dong Q. Targeting cytosolic phospholipase A2 α in colorectal cancer cells inhibits constitutively activated protein kinase B (AKT) and cell proliferation. Oncotarget. 2014 Dec 15;5(23):12304-16. PubMed PMID: 25365190; PubMed Central PMCID: PMC4322978. 6: Burke JE, Babakhani A, Gorfe AA, Kokotos G, Li S, Woods VL Jr, McCammon JA, Dennis EA. Location of inhibitors bound to group IVA phospholipase A2 determined by molecular dynamics and deuterium exchange mass spectrometry. J Am Chem Soc. 2009 Jun 17;131(23):8083-91. doi: 10.1021/ja900098y. PubMed PMID: 19459633; PubMed Central PMCID: PMC2762749. 7: Hua S, Yao M, Vignarajan S, Witting P, Hejazi L, Gong Z, Teng Y, Niknami M, Assinder S, Richardson D, Dong Q. Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells. Biochim Biophys Acta. 2013 Jun;1831(6):1146-57. doi: 10.1016/j.bbalip.2013.02.011. PubMed PMID: 23500889.

View History

UNC4976

MedKoo CAT#: 533636

CAS#: N/A